[1]
Nelson AE. Osteoarthritis year in review 2017: clinical. Osteoarthritis and cartilage. 2018 Mar:26(3):319-325. doi: 10.1016/j.joca.2017.11.014. Epub 2017 Dec 8
[PubMed PMID: 29229563]
[2]
Smith SR, Deshpande BR, Collins JE, Katz JN, Losina E. Comparative pain reduction of oral non-steroidal anti-inflammatory drugs and opioids for knee osteoarthritis: systematic analytic review. Osteoarthritis and cartilage. 2016 Jun:24(6):962-72. doi: 10.1016/j.joca.2016.01.135. Epub 2016 Feb 1
[PubMed PMID: 26844640]
Level 2 (mid-level) evidence
[3]
Henroitin Y, Reginster JY. In-vitro differences among nonsteroidal antiinflammatory drugs in their activities related to osteoarthritis pathophysiology. Osteoarthritis and cartilage. 1999 May:7(3):355-7
[PubMed PMID: 10329331]
[4]
Reichenbach S, Sterchi R, Scherer M, Trelle S, Bürgi E, Bürgi U, Dieppe PA, Jüni P. Meta-analysis: chondroitin for osteoarthritis of the knee or hip. Annals of internal medicine. 2007 Apr 17:146(8):580-90
[PubMed PMID: 17438317]
Level 1 (high-level) evidence
[5]
Vlad SC, LaValley MP, McAlindon TE, Felson DT. Glucosamine for pain in osteoarthritis: why do trial results differ? Arthritis and rheumatism. 2007 Jul:56(7):2267-77
[PubMed PMID: 17599746]
[6]
Zhu X, Sang L, Wu D, Rong J, Jiang L. Effectiveness and safety of glucosamine and chondroitin for the treatment of osteoarthritis: a meta-analysis of randomized controlled trials. Journal of orthopaedic surgery and research. 2018 Jul 6:13(1):170. doi: 10.1186/s13018-018-0871-5. Epub 2018 Jul 6
[PubMed PMID: 29980200]
Level 1 (high-level) evidence
[7]
Richmond J, Hunter D, Irrgang J, Jones MH, Levy B, Marx R, Snyder-Mackler L, Watters WC 3rd, Haralson RH 3rd, Turkelson CM, Wies JL, Boyer KM, Anderson S, St Andre J, Sluka P, McGowan R, American Academy of Orthopaedic Surgeons. Treatment of osteoarthritis of the knee (nonarthroplasty). The Journal of the American Academy of Orthopaedic Surgeons. 2009 Sep:17(9):591-600
[PubMed PMID: 19726743]
[8]
Kantor ED, Lampe JW, Navarro SL, Song X, Milne GL, White E. Associations between glucosamine and chondroitin supplement use and biomarkers of systemic inflammation. Journal of alternative and complementary medicine (New York, N.Y.). 2014 Jun:20(6):479-85. doi: 10.1089/acm.2013.0323. Epub 2014 Apr 16
[PubMed PMID: 24738579]
[9]
Meulyzer M, Vachon P, Beaudry F, Vinardell T, Richard H, Beauchamp G, Laverty S. Comparison of pharmacokinetics of glucosamine and synovial fluid levels following administration of glucosamine sulphate or glucosamine hydrochloride. Osteoarthritis and cartilage. 2008 Sep:16(9):973-9. doi: 10.1016/j.joca.2008.01.006. Epub 2008 Mar 4
[PubMed PMID: 18295513]
[10]
Henrotin Y, Mobasheri A, Marty M. Is there any scientific evidence for the use of glucosamine in the management of human osteoarthritis? Arthritis research & therapy. 2012 Jan 30:14(1):201. doi: 10.1186/ar3657. Epub 2012 Jan 30
[PubMed PMID: 22293240]
[11]
Yoshimura M, Sakamoto K, Tsuruta A, Yamamoto T, Ishida K, Yamaguchi H, Nagaoka I. Evaluation of the effect of glucosamine administration on biomarkers for cartilage and bone metabolism in soccer players. International journal of molecular medicine. 2009 Oct:24(4):487-94
[PubMed PMID: 19724889]
[12]
Henrotin Y, Chevalier X, Herrero-Beaumont G, McAlindon T, Mobasheri A, Pavelka K, Schön C, Weinans H, Biesalski H, Participants at the Hohenheim Consensus Conference in August 29th 2011. Physiological effects of oral glucosamine on joint health: current status and consensus on future research priorities. BMC research notes. 2013 Mar 26:6():115. doi: 10.1186/1756-0500-6-115. Epub 2013 Mar 26
[PubMed PMID: 23531101]
Level 3 (low-level) evidence
[13]
Goldring MB, Otero M. Inflammation in osteoarthritis. Current opinion in rheumatology. 2011 Sep:23(5):471-8. doi: 10.1097/BOR.0b013e328349c2b1. Epub
[PubMed PMID: 21788902]
Level 3 (low-level) evidence
[15]
Knudsen JF, Sokol GH. Potential glucosamine-warfarin interaction resulting in increased international normalized ratio: case report and review of the literature and MedWatch database. Pharmacotherapy. 2008 Apr:28(4):540-8. doi: 10.1592/phco.28.4.540. Epub
[PubMed PMID: 18363538]
Level 3 (low-level) evidence
[16]
Gray HC, Hutcheson PS, Slavin RG. Is glucosamine safe in patients with seafood allergy? The Journal of allergy and clinical immunology. 2004 Aug:114(2):459-60
[PubMed PMID: 15341031]
[17]
Cerda C, Bruguera M, Parés A. Hepatotoxicity associated with glucosamine and chondroitin sulfate in patients with chronic liver disease. World journal of gastroenterology. 2013 Aug 28:19(32):5381-4. doi: 10.3748/wjg.v19.i32.5381. Epub
[PubMed PMID: 23983444]